Mechanical Cough Assist Plus NIV After Extubation Tested in ICU Trial
A terminated multicenter RCT examined whether mechanical cough assistance plus NIV could cut re-intubation rates in ICU patients with weak cough.
Summary
When ICU patients are taken off a breathing tube, a weak cough dramatically raises their risk of needing re-intubation. This French multicenter randomized trial tested whether combining a mechanical cough-assist device with non-invasive ventilation could outperform standard post-extubation care — manual chest physiotherapy plus selective NIV — in reducing 48-hour re-intubation rates. The study focused specifically on patients objectively identified as having low cough strength before extubation, using a cough peak flow threshold below 60 liters per minute measured via the ventilator's built-in flow meter. The trial was ultimately terminated before completion, leaving the core question unanswered. Identifying and proactively managing weak cough remains a critical challenge in ICU weaning protocols with direct implications for patient mortality and morbidity.
Detailed Summary
Extubation failure in the ICU is a serious and underappreciated clinical problem. When patients who have been mechanically ventilated are taken off the breathing tube prematurely or without adequate preparation, the consequences can be severe — prolonged ventilation, increased infection risk, higher mortality, and greater resource utilization. One of the most underestimated predictors of re-intubation is weak cough, which compromises the patient's ability to clear secretions after the tube is removed.
This French multicenter randomized trial, sponsored by Hospices Civils de Lyon, was designed to address this gap head-on. Investigators enrolled ICU patients with objectively confirmed low cough strength — defined as a cough peak flow below 60 L/min, measured using the ventilator's built-in flow meter. The experimental arm combined mechanical cough assistance with systematic non-invasive ventilation post-extubation. The control arm received the current standard of care: manual physiotherapy drainage and NIV reserved for specific clinical indications.
The primary outcome was re-intubation rate within 48 hours of extubation. By targeting a high-risk subgroup identifiable before extubation, the trial aimed to provide a pragmatic, prevention-focused protocol. The mechanical cough-assist approach is already validated in chronic neuromuscular disease but had not been rigorously studied in general ICU populations.
Unfortunately, the trial was terminated before reaching its enrollment goals, meaning no definitive efficacy data were generated. The reasons for termination are not disclosed in the available abstract. This leaves a significant evidence gap: it is still unclear whether systematic mechanical cough assistance improves outcomes for this vulnerable ICU subgroup.
Despite termination, the trial highlights an important clinical principle — proactive, objective assessment of cough strength before extubation could change ICU weaning practice. Cough peak flow measurement is simple, reproducible, and already feasible with standard ventilators. Future trials are needed to validate this interventional strategy.
Key Findings
- Cough peak flow below 60 L/min identifies ICU patients at high risk for post-extubation re-intubation.
- Ventilator built-in flow meters can reliably measure cough peak flow, making objective assessment practical.
- The trial was terminated early, leaving the efficacy of mechanical cough assist plus NIV unproven.
- Standard care post-extubation relies on manual physiotherapy and selective NIV, which may be insufficient for weak-cough patients.
- Mechanical cough assistance devices are established in neuromuscular disease but lack validation in general ICU populations.
Methodology
Open-label multicenter randomized controlled trial comparing mechanical cough assistance plus systematic NIV versus standard post-extubation care in ICU patients with cough peak flow below 60 L/min. The primary endpoint was re-intubation rate at 48 hours post-extubation. The trial was terminated early by the sponsor (Hospices Civils de Lyon) before reaching its planned enrollment.
Study Limitations
The trial was terminated before completion, meaning no efficacy conclusions can be drawn and the primary question remains unanswered. The summary is based on the abstract only; reasons for termination, enrollment numbers, and any interim results are not available. Single-country design and open-label methodology may limit generalizability and introduce performance bias.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.